Australian researchers identify a link between itchy skin and gut pain, caused by identical receptors
This is big news for Irritable Bowel Syndrome (IBS) patients: 11 percent of the world’s population suffers from IBS, but the fight against chronic pain has taken a major step forward with scientists identifying receptors in the nervous system which cause the condition in the hope of developing effective treatments.
Flinders University researchers at SAHMRI have discovered receptors that cause itchy skin also exist in the human gut and activate neurons, which result in IBS patients feeling like they’re experiencing chronic gut pain or a seriously painful ‘gut itch.’
In millions of Americans with IBS, it looks like these ‘itch’ receptors might be more present than in healthy people. This means that more neurons are activated, causing the feeling of more pain.
NHMRC and Matthew Flinders Research Fellow in Gastrointestinal Neuroscience, Professor Stuart Brierley, says these gut itch receptors could offer a new way of targeting the underlying cause of gut pain, rather than using traditional drugs (like opioids), which don’t fix the problem right now.
“We found receptors which bring about an itchy feeling on skin also do the same in in the gut, so these patients are essentially suffering from a ‘gut itch’. We’ve translated these results to human tissue tests and now hope to help create a treatment where people can take an oral medication for IBS.”
“Patients with IBS suffer from chronic abdominal pain and experience rewiring of their nervous system so they feel pain when they shouldn’t – we decided to ask important questions about how nerves in the gut are activated to cause pain in order to seek out potential solutions.”
Professor Brierley, also the Director of the Visceral Pain Research Group at SAHMRI, says pain experienced by IBS sufferers takes place when itch receptors are coupled with what’s known as the ‘wasabi receptor’ in the nervous system, which normally helps people react to consuming wasabi- the Japanese condiment.
“If you think about what happens when you eat wasabi, it activates a receptor on the nerves and sends a pain signal – that’s exactly what’s happening within in their gut as they experience an itchy effect or wasabi effect in the gut.”
“Having shown these mechanisms contribute to chronic gut pain, we can now work out ways to block these receptors and thereby stop the ‘gut itch’ signal traveling from the gut to the brain. This will be a far better solution that the problems currently presented by opioid treatments”.
The Latest on: irritable bowel syndrome
via Google News
The Latest on: Irritable bowel syndrome
- Arena Pharmaceuticals Reports Topline Results from Phase 2b CAPTIVATE Clinical Trialon March 3, 2021 at 10:07 pm
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the randomized, double-blind, placebo-controlled Phase 2b CAPTIVATE clinical trial evaluating three doses of olorinab, a ...
- BioFit Probiotic Reviews – Effective Ingredients or Cheap Supplement? 2021 Reviewon March 3, 2021 at 1:23 pm
BioFit is a daily probiotic supplement by Nature's Formula that targets healthy body weight management safely to create a better climate for digestion using clinically-studied ingredients. BioFit ...
- Arena Pharma's Olorinab Fails To Top Placebo In IBS-Related Abdominal Painon March 3, 2021 at 10:09 am
Arena Pharmaceuticals Inc (NASDAQ: ARNA) has announced topline data from Phase 2b CAPTIVATE trial evaluating olorinab for abdominal pain due to Irritable Bowel Syndrome (IBS). Although olorinab was ...
- Arena (ARNA) Tumbles as Mid-Stage Gastrointestinal Study Failson March 3, 2021 at 9:40 am
Arena Pharmaceuticals ARNA announced that its phase IIb CULTIVATE study evaluating cannabinoid receptor 2 agonist candidate, olorinab, in patients with abdominal pain due to irritable bowel syndrome ...
- The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Studyon March 3, 2021 at 5:00 am
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 2) ...
- Arena's pain drug fails phase 2b, prompting review of 'strategic options'on March 3, 2021 at 4:40 am
A phase 2b clinical trial of Arena Pharmaceuticals’ olorinab has missed its primary endpoint. The cannabinoid receptor 2 agonist failed to reduce abdominal pain in the overall population of irritable ...
- Heali App Shown to Improve Quality of Life by 2.6x in Patients with Irritable Bowel Syndrome in Randomized Controlled Trialon March 2, 2021 at 10:08 am
A new study published in the Journal of Medical Internet Research finds preliminary evidence that Heali, an app that uses artificial intelligence (AI) to make personalized nutrition simple, may ...
- Knight Therapeutics Announces Canadian Commercial Launch of IBSRELA(TM) - New Innovative Treatment for Irritable Bowel Syndrome with Constipationon March 1, 2021 at 10:32 pm
MONTREAL, March 01, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today the Canadian commercial ...
- IBS Treatment Market 2021 : Latest Industry Trends, Growth, Share, Size and 2026 Forecast Research Report with Top countries Dataon March 1, 2021 at 7:50 pm
According to 360 Research Reports, the “ IBS Treatment Market " 2021 by Types (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Ramosetron Hydrochloride, Others), Application (Diarrhea-predominant ...
- Antidepressants could be prescribed by GPs as the new weapon in the war on Irritable Bowel Syndromeon February 27, 2021 at 2:01 pm
IBS affects nine million Britons, causing agonising pain, bloating, diarrhoea and constipation - with few effective treatments available.
via Bing News